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ABSTRACT 
Major depressive disorder (MDD) is clinically heterogeneous with prevalence rates twice as 
high in women as in men. There are many possible sources of heterogeneity in MDD most of 
which are not measured in a sufficiently comparable way across study samples. Here, we 
assess genetic heterogeneity based on two fundamental measures, between-cohort and 
between-sex heterogeneity. First, we used genome-wide association study (GWAS) summary 
statistics to investigate between-cohort genetic heterogeneity using the 29 research cohorts 
of the Psychiatric Genomics Consortium (PGC; N cases = 16,823, N controls = 25,632) and 
found that some of the cohort heterogeneity can be attributed to ascertainment differences 
(such as recruitment of cases from hospital vs community sources). Second, we evaluated 
between-sex genetic heterogeneity using GWAS summary statistics from the PGC, Kaiser 
Permanente GERA, UK Biobank and the Danish iPSYCH studies but did not find convincing 
evidence for genetic differences between the sexes. We conclude that there is no evidence 
that the heterogeneity between MDD data sets and between sexes reflects genetic 
heterogeneity. Larger sample sizes with detailed phenotypic records and genomic data 
remain the key to overcome heterogeneity inherent in assessment of MDD. 
 
KEYWORDS: MDD, depression, genetic heterogeneity, sex differences, LD score regression. 
 
INTRODUCTION 
Major Depressive Disorder (MDD) is a common debilitating disorder with lifetime risk of ~15% 
(R. C. Kessler & Bromet, 2013; Lohoff, 2010). Genetic factors contribute to etiology of MDD 
with heritability estimated to be ~37% (Kendler, Gatz, Gardner, & Pedersen, 2006; Sullivan, 
Neale, & Kendler, 2000) of which about one-third is tracked by common-genetic variants 
(Cross-Disorder Group of the Psychiatric Genomics et al., 2013; Wray et al., 2018). Non-
genetic factors also contribute and environmental risk factors include childhood 
psychological trauma (Chapman et al., 2004; Heim, Newport, Mletzko, Miller, & Nemeroff, 
2008; Vythilingam et al., 2002), social isolation (Bruce & Hoff, 1994), and medical conditions, 
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such as cardiovascular disease (Fiedorowicz, 2014; Fraguas Jr et al., 2007; Huffman, Celano, 
Beach, Motiwala, & Januzzi, 2013). Most complex disorders are considered to be 
heterogeneous at clinical presentation. For MDD, heterogeneity is inherent in the diagnostic 
framework since diagnosis is achieved through different combinations of endorsements of at 
least five out of nine criteria in the context of depressed mood for most of the day every day 
for two weeks (Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria). 
Heterogeneity in symptom profiles between individuals reflects not only the symptoms 
endorsed, but for some criteria (those assessing sleep, weight/appetite and psychomotor 
function) the endorsement can reflect either increase or decrease (or both). It is plausible 
that these clinical differences reflect different biological pathways.  The lack of a biological 
“gold standard” definition in psychiatric illness is well recognised (Kapur, Phillips, & Insel, 2012), 
and a key question for the field is whether genetic heterogeneity underpins phenotypic 
heterogeneity (Fanous & Kendler, 2005), and if genome-wide genetic data can support 
analyses that demonstrate genetic heterogeneity (Han et al., 2016).  Here, we assess genetic 
heterogeneity based on two fundamental measures available to us, between-cohort and 
between-sex heterogeneity. While non-biological factors (such as ascertainment strategy) 
could contribute to both between-cohort and between-sex heterogeneity, evidence for 
between-sex heterogeneity may reflect, at least in part, biological differences. 
 
Prevalence rates of MDD in women that are double those of men are consistently reported in 
epidemiological studies, with lifetime risk approximately 0.2 for females and 0.1 for males 
(Ronald C. Kessler, 2003) Women tend to have younger age of onset, greater comorbidity 
with panic and other anxiety disorders, whereas men exhibit stronger comorbidity with 
alcohol dependence or abuse (Schuch, Roest, Nolen, Penninx, & de Jonge, 2014). Attempts 
to link the epidemiological differences to biological differences have been less consistent. 
Some twin studies reported significantly higher heritability in females (0.42, 95% CI=0.36-0.47) 
than males (0.29, 95% CI=0.19-0.38), and with genetic correlation significantly different from 1 
(rg~0.60, 95% CI=0.31-0.99) (Kendler et al., 2006). Other studies failed to find differences 
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between sexes (Fernandez-Pujals et al., 2015).  Drawing strong conclusions may be 
confounded by reporting biases as males are more likely to under-report their symptoms 
when compared to females (Hunt, Auriemma, & Cashaw, 2003; Thornicroft et al., 2017). 
 
We use genome-wide association study (GWAS) summary statistics data to investigate 
genetic heterogeneity of MDD. We study between-cohort genetic heterogeneity using data 
from the 29 independent studies that comprise the wave 2 PGC-MDD study (PGC29 (Wray et 
al., 2018)). We also investigate genetic heterogeneity by sex using GWAS summary statistics 
from PGC29 and three other large data sets. We evaluate between-cohort and between-
sex genetic heterogeneity estimates of SNP-heritabilities and genetic correlations. These 
estimates of genetic parameters, calculated from genome-wide data, provide single statistic 
summaries of the data. Specifically, differences in SNP-heritability estimates between samples 
could imply real differences in the relative magnitude of genetic risk effect sizes between 
samples or could reflect biases due to ascertainment characteristics of the sample. In 
contrast, an estimate of a genetic correlation less than one may reflect differences in the 
relative ordering of genetic risk effects between samples. It is possible for SNP-heritabilities to 
differ between samples but the genetic correlations to be one. 
 
MATERIALS & METHODS 
Between-cohort heterogeneity 
We investigate heterogeneity between cohorts from the PGC Working Group for MDD (PGC-
MDD) (Major Depressive Disorder Working Group of the Psychiatric et al., 2013), which 
comprises 29 cohorts  (PGC29, 10 from wave 1 (Major Depressive Disorder Working Group of 
the Psychiatric et al., 2013) and 19 from wave 2 (Wray et al., 2018)), totalling 16,815 cases 
(68% female) and 25,485 controls (51% female) (Table 1, Supplementary Table 1).  Cohorts 
represent individual studies in which cases and controls were imputed together to the 1000 
Genomes reference panel (Genomes Project et al., 2010) from a common set of SNPs that 
had been processed through a common quality control (QC) pipeline (Wray et al., 2018). For 
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the majority of cohorts (but not all), cases and controls were collected by the same research 
group and were genotyped together on the same genotyping array. All 29 case cohorts 
passed a structured methodological review by MDD assessment experts (DF Levinson and KS 
Kendler). Cases were required to meet international consensus criteria (DSM-IV, International 
Statistical Classification of Diseases (ICD)-9, or ICD-10) (American Psychiatric Association, 
1994; World Health Organization, 1978, 1992) for a lifetime diagnosis of MDD established using 
structured diagnostic instruments from assessments by trained interviewers, clinician-
administered checklists, or medical record review. Nonetheless, there were differences in 
ascertainment across cohorts (Supplementary Table 1). For example the RADIANT cohort 
(rad3) (C. M. Lewis et al., 2010) recruited cases of clinically assessed recurrent MDD, which 
being more severe have lower lifetime risk ~5% (McGuffin, Katz, Watkins, & Rutherford, 1996), 
compared to community samples such as the QIMR cohorts (qi3c, qi6c, qio2) assessed by 
self-report interview and with lifetime risk ~24% (Mosing et al., 2009). To capture heterogeneity 
due to ascertainment, we coded the 29 cohorts as identified in community, psychiatric 
outpatient, psychiatric inpatients, or mixed in-/out-patient settings (Supplementary Table 1). 
 
Between-sex heterogeneity 
We investigate between sex heterogeneity using four large MDD data sets (Table 1). In 
addition to PGC29, we used the Genetic Epidemiology Research on Adult Health and Aging 
(GERA) Cohort (Banda et al., 2015) (where electronic medical records from the Kaiser 
Permanente healthcare system were used to identify cases as individuals being treated 
clinically for MDD, and controls had no recorded treatment for any psychiatric disorder), the 
Danish iPSYCH cohort (where national hospital records identified cases as those ever treated 
clinically for MDD and controls as those who have not), and the volunteer UK Biobank  
(Bycroft et al., 2018; Lane et al., 2016) (UKB) study. UKB cases were those with either recorded 
ICD10 codes for MDD (F32, F33) or self-report for seeking treatment for nerves, anxiety or 
depression; for detailed description of the “broad depression” definition see reference 
(Howard et al., 2018)). Exclusions for both cases and controls were those with recorded 
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schizophrenia, bipolar or mental retardation diagnoses or prescriptions associated with these 
disorders. Additional exclusions for controls included those with recorded anxiety, phobic or 
autistic spectrum disorders. In all studies, cases and controls were unrelated. GWAS summary 
statistics for each cohort used the same methods as for PGC29. 
 
Statistical methods 
We use GWAS summary statistics and linkage disequilbrium (LD) score analysis (LDSC) (B. K. 
Bulik-Sullivan et al., 2015) to estimate the total proportion of variance in liability attributable to 
SNPs genome-wide (i.e., SNP-heritability). Bivariate LDSC was used to estimate the genetic 
correlation tagged by genome-wide SNPs (rg) between two traits. LDSC has been applied 
widely to GWAS summary statistics of psychiatric (Anttila et al., 2018) and other disorders (B. 
Bulik-Sullivan et al., 2015), and results have been shown to agree well with estimates made 
from full individual-level genotype and phenotype data using linear mixed model analysis 
(e.g., GREML (Yang et al., 2010)), as long as the LD reference sample is drawn from a 
population that appropriately reflects the samples contributing the GWAS summary 
statistics(Yang et al., 2015). A key advantage of LDSC is the minimal computational 
requirements compared to methods that use individual level data, and the ability to 
differentiate between genomic inflation due to polygenicity and due to population 
stratification. Disadvantages of LDSC are that standard errors (s.e.) of estimates can be 
(about 50%) higher compared to when estimates are based on full data, particularly for rg 
estimates (Ni, Moser, Schizophrenia Working Group of the Psychiatric Genomics, Wray, & Lee, 
2018).  
 
SNP-heritability is estimated on the observed binary scale ℎ𝑆𝑁𝑃−𝑐𝑐
2 , but these estimates 
depend on the proportion of cases in the sample (P) and so are not easily comparable 
across cohorts. Hence, for improved interpretability and comparison across studies, ℎ𝑆𝑁𝑃−𝑐𝑐
2  is 
transformed to the liability scale ℎ𝑆𝑁𝑃
2   (Lee, Wray, Goddard, & Visscher, 2011) based on 
normal distribution theory, given an assumed lifetime risk of disease in the population(K): 
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ℎ𝑆𝑁𝑃
2 = ℎ𝑆𝑁𝑃−𝑐𝑐
2  
(𝐾(1−𝐾))2
𝑃(1−𝑃)𝑧2
     [1] 
where z is the height of the standard normal density function when truncated at proportion 
K. However, this transformation assumes that controls are screened. Peyrot et al (2016) 
(Peyrot, Boomsma, Penninx, & Wray, 2016) showed that when the proportion of controls that 
are unscreened is u, then transformation should be   
ℎ𝑆𝑁𝑃
2 = ℎ𝑆𝑁𝑃−𝑐𝑐
2  
(𝐾(1−𝐾))2
𝑃(1−𝑃)(1−𝑢𝐾)2𝑧2
     [2] 
which reduces to equation [1] when all controls are screened, u = 0. When diseases are 
uncommon, assuming controls are screened when they are not makes little impact(Peyrot et 
al., 2016). However, for very common disorders, such as MDD, the difference is not trivial. For 
example, for K = 0.15,  ℎ𝑆𝑁𝑃−𝑐𝑐
2 = 0.15, P = 0.5, then ℎ𝑆𝑁𝑃
2 = 0.18 when controls are screened and 
0.24 when unscreened. The rg estimates are robust to P, K and u, since these factors 
contribute to both numerator and denominator of the correlation (which is defined as the 
estimate of the additive genetic covariance divided by the product of the square root of the 
SNP-heritabilities for the two traits). Hence rg estimates are robust to ascertainment practices 
and approximately the same where estimated on the case-control observed scale or liability 
scales (B. Bulik-Sullivan et al., 2015). If the same genetic effects contribute to disease risk 
between sexes or between cohorts then rg is expected to be 1.  
 
It was not possible to compare ℎ𝑆𝑁𝑃
2  of each PGC29 cohort, because the per-cohort 
estimates had high s.e. (e.g. a cohort of 500 cases and 500 controls would be expected  to 
produce ℎ𝑆𝑁𝑃
2  with standard error of at minimum 0.38 (Visscher et al., 2014)). Instead we 
estimated the ℎ𝑆𝑁𝑃
2  attributed to a cohort by evaluating its contribution to ℎ𝑆𝑁𝑃
2  estimates 
calculated from 500 random samplings of cohorts drawn from the 29 PGC29 cohorts. In each 
sampling, we randomly selected cohorts until the total sample size was  5000, then used the 
GWAS summary statistics meta-analysed (weighted by s.e.) in LDSC to estimate  ℎ𝑆𝑁𝑃
2  
assuming lifetime risk of K = 0.15, and assuming controls are screened (equation [1]). To 
determine the contribution to the ℎ𝑆𝑁𝑃
2  estimate from each cohort we fitted a linear model 
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with estimated ℎ𝑆𝑁𝑃
2  as the dependent variable regressed on indicator variables set as 1 if the 
cohort contributed to the estimate (was included in the random sampling), and 0 otherwise. 
 
RESULTS 
Between-cohort heterogeneity within PGC29 
We estimated ℎ𝑆𝑁𝑃
2  in 500 random samplings of the cohorts from PGC29. From a linear 
regression of ℎ𝑆𝑁𝑃
2  on indicator variables set as 1 if the cohort contributed to the estimate and 
0 if it did not, we estimated an ℎ𝑆𝑁𝑃
2  effect size deviation per cohort (y-axis Figure 1). Fifteen of 
the 29 cohorts had ℎ𝑆𝑁𝑃
2  deviations different from zero (p < 0.05/29). We found that the cohorts 
nes1 (combined sample of the Netherlands Study of Depression and Anxiety and the 
Netherlands Twin Registry) (Boomsma et al., 2008; Penninx et al., 2008) and gep3 
(GenPod/NEWMEDS) (G. Lewis et al., 2011) contributed most to variation in estimates of ℎ𝑆𝑁𝑃
2 , 
and explain 0.14 and 0.16, respectively, of the variance in ℎ𝑆𝑁𝑃
2  estimates across the 500 
samplings. Samplings that included cohort nes1 had the highest average estimates of ℎ𝑆𝑁𝑃
2 , 
while samplings including gep3 had the lowest average estimates. These differences are in line 
with expectations based on screening strategies for controls (Supplementary Table 1). The nes1 
cohort used super-screened controls (Boomsma et al., 2008), such that controls never scored 
higher than 0.65 on a general factor score for anxious depression (mean =0, SD=0.7) derived 
from a combined measure of neuroticism, anxiety, and depressive symptoms assessed via 
longitudinal questionnaires over 15 years. In contrast, the gep3 cohort was a case-only 
research cohort which was matched to independently collected and genotyped controls 
(hence particularly stringent QC is needed to combine the genotype data of the contributing 
cases and controls). In fact, gep3 is one of seven cohorts for which controls were unscreened 
for MDD (Figure 1), but only one other cohort used independently genotyped controls (STAR*D, 
coded as stm2); together the seven cohorts have lower mean beta-values, but not 
significantly so (p=0.055). The trend in these results might be explained by recognising that SNP-
heritability is first estimated on the observed binary case-control scale ℎ𝑆𝑁𝑃−𝑐𝑐
2  and then 
transformed to the liability scale ℎ𝑆𝑁𝑃
2 . Indeed, we find that increasing sample prevalence (P in 
 9 
equation 1) is significantly associated with the estimated ℎ𝑆𝑁𝑃
2   (p=0.00057), but not sex ratio 
(p=0.72). The application of the standard transformation (equation [1]), as we have done, 
assumes screened controls and could generate an under-estimate of the SNP-heritability if 
controls were in fact unscreened. Similarly, super-screening of controls could generate an 
over-estimate of the true ℎ𝑆𝑁𝑃
2 . Hence, we expect that the standard transformation would 
generate an overestimate for the nes1 cohort (super-screened controls) and an 
underestimate for cohorts with unscreened controls, consistent with our results.  
 
Next, we investigated if ℎ𝑆𝑁𝑃
2  estimates differed based on the research protocol to ascertain 
cases. For the same proportion of cases and controls in the GWAS sample, we would expect 
the ℎ𝑆𝑁𝑃−𝑐𝑐
2  to be higher for a clinically ascertained cohort than a community ascertained 
cohort, further we would expect the transformation based on K = 0. 15 (equation [1]) to 
overestimate ℎ𝑆𝑁𝑃
2 when the true K is lower (clinical cohort) and underestimate ℎ𝑆𝑁𝑃
2 when the 
true K is higher (community cohort). There is evidence to support this hypothesis (Figure 1). 
We found significant difference between the mean estimates of community (-0.027, s.e. 
0.007) vs non-community cohorts (-0.08 s.e. 0.006) (with non-community comprising the three 
in- and out-patient categories), using a one-sided, two-sample t-test assuming unequal 
variance (p=0.028) (Supplementary Table 4). The difference became more significant 
(p=0.015) when the cohorts we had a priori reason to exclude, namely nes1 and gep3, 
based on discussions above were removed. 
 
Between-sex heterogeneity 
Using the four large data sets (Table 1) we investigate sex-specific heterogeneity. We used 
bivariate LDSC to estimate the rg between all pairs of the two sexes by four data sets, but the 
standard errors were high (Supplementary Table 2). rg involving the GERA_M data set were 
not estimable, because of the negative/zero of ℎ𝑆𝑁𝑃
2  used in the denominator of the rg 
estimate. The between-sex rg estimated from the meta-analysis of the GWAS summary 
statistics of the 4 data sets was 0.86 (s.e. 0.04; pH0:rg=1= 3.0x10-4), and the meta-analysis of 12 
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male-female rg estimates from all pairs of data sets was 0.76 (s.e. 0.03; pH0:rg=1= 8.9 x10-16).  At 
face value these results imply genetic factors are only partially shared between the sexes.  
However, this interpretation should be considered with caution when benchmarked by the 
meta-analysis of 6 female-female rg estimates of 0.72 (s.e. 0.04; pH0:rg=1= 4.9 x 10-11) and the 
meta-analysis of 3 male-male rg estimates of 0.71 (s.e. 0.11; pH0:rg=1= 0.11).  Hence, the 
between-sex estimate of rg being significantly different from zero likely reflects the general 
heterogeneity between the data sets rather than being sex-specific.  
 
Next, we investigated sex-specific estimates of ℎ𝑆𝑁𝑃
2  using LDSC (Table 2, Supplementary 
Table 3) to determine if there is evidence for a greater genetic contribution to MDD risk in 
females then males. We have power to detect differences of the order of 2*(s.e. of male 
estimate + s.e. of female estimate).  Initially, in the transformation of the ℎ𝑆𝑁𝑃−𝑐𝑐
2  estimate to 
the liability scale (equation [1]) we assumed K = 0.20 for females and K =0.10 for males (Table 
2), consistent with literature reports that MDD is twice as common in females as males 
(Weissman, Leaf, Holzer, Myers, & Tischler, 1984). The ℎ𝑆𝑁𝑃
2  estimates were smaller for males 
(range -0.02 to 0.15) than for females (range 0.10 to 0.23), but given the magnitude of the 
standard errors, none of the ℎ𝑆𝑁𝑃
2  sex differences were significantly different for any individual 
data set. However, meta-analysis of the ℎ𝑆𝑁𝑃
2  estimates of the four data sets did lead to 
estimates that were significantly different (Meta-4 in Table 2; 0.07 in males vs. 0.11 in females, 
p=1.6x10-6). In addition, ℎ𝑆𝑁𝑃
2  estimated from the meta-analysed GWAS results of the 4 data 
sets also showed significant difference between males and females (0.06 vs 0.08, p = 7.3x10-4; 
Table 2 GWAS-Meta). We also meta-analysed the six ℎ𝑆𝑁𝑃
2  values estimated from the genetic 
covariance between pairs of same-sex data sets in bivariate LDSC analysis. Since the traits 
are (presumed to be) the same, the genetic covariance is also an estimate of genetic 
variance (Supplementary Table 3; Table 2 Meta-6). This again showed lower mean estimates 
for males with a significant difference between the sexes (0.07 in males vs 0.11 in females, 
p=0.0012). For completeness, a meta-analysis from all 10 of the estimates is provided (Table 2 
Meta-10); this uses the same data sets as the GWAS-Meta, but the latter uses all the 
 11 
information jointly rather than pairwise. Before drawing strong conclusions from these results, 
it is important to recognise that the estimates of ℎ𝑆𝑁𝑃
2  depend on the choice of the lifetime risk 
estimates (K in equations [1] and [2]) (Figure 2). The point estimates are more similar if the 
same lifetime risk is assumed between the sexes, but it is difficult to justify such an assumption, 
because it is not, at face value, supported by epidemiological data. However, since 
depression maybe under-reported in males (Martin, Neighbors, & Griffith, 2013; Thornicroft et 
al., 2017), for illustration purposes we could assume the true lifetime risk of MDD is the same 
between the sexes (K =0.20), but that through under-reporting the controls are contaminated 
by 0.10 of cases (Equation [2], u=0.1). Under these assumptions, the  ℎ𝑆𝑁𝑃
2  estimates are not 
significantly different between the sexes for any data set (Figure 2, Table 2). 
 
Last, we estimated X-chromosome SNP-heritability from the meta-analysed cohorts  for males 
and females separately. However, the standard errors of the estimates were large relative to 
the  ℎ𝑆𝑁𝑃
2   estimates (ℎ𝑆𝑁𝑃
2  𝑚𝑎𝑙𝑒𝑠=0.0025 (se=0.06); ℎ𝑆𝑁𝑃
2  𝑓𝑒𝑚𝑎𝑙𝑒𝑠=0.0005 (se=0.03), which meant 
estimation of the rg between them was not meaningful.  
 
 
DISCUSSION 
Heterogeneity in MDD is often discussed, but hard to investigate. In a novel set of analyses, 
we explored the heterogeneity of MDD using genetic data. The first set of analyses 
contrasted 29 PGC cohorts, by estimating their average contribution to estimates of ℎ𝑆𝑁𝑃
2  
from repeated random samplings of cohorts selected into GWAS meta-analyses. While we 
found notable differences between cohorts in the ℎ𝑆𝑁𝑃
2  contribution estimates (Figure 1), 
these differences could be explained, at least partly, via knowledge of cohort ascertainment 
practices: higher contributions for cohorts ascertained in clinical compared to community 
settings (Figure 1, p=0.028), higher contribution from a sample known to use super-screened 
controls (nes1), and a trend towards lower contributions from samples that used unscreened 
controls. One conclusion is that known cohort information about case ascertainment status 
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could be included usefully in analysis methods to increase power. A framework for such an 
analysis has been proposed (Zaitlen et al., 2012), but in practice the necessary parameters 
relating to cohort specific risks are usually unknown. In the seven samples contributing to the 
published PGC meta-analysis (PGC29, GERA, iPSYCH, UK Biobank, deCode, Generation 
Scotland, 23andMe) (Wray et al., 2018), ℎ𝑆𝑁𝑃
2  estimates ranged from 0.09 to 0.25 and the 
weighted mean rg for all pairwise combinations was 0.76 (s.e. = 0.03), which is significantly 
different from one. The cohorts had different recruitment strategies with ascertainment 
ranging from self-report to national hospital records. Moreover, even within the wave 1 PGC-
MDD research cohorts endorsement proportions of the nine DSMIV criteria showed 
considerable heterogeneity including between cohorts that had similar clinical 
ascertainment strategies(Major Depressive Disorder Working Group of the Psychiatric et al., 
2013). For example, endorsement rates of 56%, 27% and 10% were recorded for the criterion 
symptom 4b, hypersomnia nearly every day, for different early onset (< 30 years) recurrent 
MDD samples(Major Depressive Disorder Working Group of the Psychiatric et al., 2013). 
Despite the heterogeneity, out-of-sample prediction demonstrated that the self-reported 
23andMe GWAS results explained variance in clinically ascertained cohorts with high 
significance (Wray et al., 2018). Sample size remains the driving force for genetic discovery in 
MDD. Ideally, larger sample sizes should be accompanied by collection of detailed, 
consistent, and longitudinal phenotypic data to enable more precise case and control 
definitions. 
 
We also investigated between-sex genetic heterogeneity. Our sex-specific analyses found 
significantly smaller ℎ𝑆𝑁𝑃
2  for males than females, a trend replicated in all four data sets, and 
hence was highly significant in the meta-analysis of the four cohort estimates (Table 2, male 
v1). However, we recognised that the comparisons of ℎ𝑆𝑁𝑃
2   between the sexes depended on 
the choice of their respective lifetime risks (Figure 2). For baseline analyses we used lifetime 
risk estimates of K = 0.20 for females and K = 0.10 for males, consistent with a 2:1 risk for 
females vs. males (Weissman et al., 1984), with higher K values generating higher ℎ𝑆𝑁𝑃
2  
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estimates. One explanation for a lower lifetime risk for males could be higher rates of under-
reporting (Martin et al., 2013; Thornicroft et al., 2017). We calculated  ℎ𝑆𝑁𝑃
2   in males assuming 
the same lifetime risk as females, but with incomplete screening of controls. Such a 
hypothetical scenario generated similar estimates of ℎ𝑆𝑁𝑃
2  between the sexes (Figure 2, Table 
2).  
In summary, our analyses demonstrate between-cohort genetic heterogeneity, but this can 
be explained, at least in part, by known factors such as case/control ascertainment. 
Investigation of between sex heterogeneity provided no convincing evidence to support 
genetic differences between the sexes. A robust conclusion is simply that large sample sizes 
will overcome sample heterogeneity as demonstrated in the latest major depression GWAS 
meta-analyses (Howard et al., 2018; Wray et al., 2018). Based on differences in lifetime 
disease risk and differences in heritability, while assuming a similar number of contributing risk 
loci, we previously estimated that sample sizes for GWAS need to be five times bigger for 
MDD than for schizophrenia (SCZ) (Wray et al., 2012).  On the one hand, heterogeneity 
between samples may push this estimate higher. On the other hand, the heterogeneity may 
already account for the higher prevalence and lower heritability. The PGC GWAS meta-
analysis for MDD/major depression based on 135K cases (Wray et al., 2018) identified 44 
independent significant loci. This compares to 145 independent loci for SCZ from or 41K cases 
(Pardiñas et al., 2018), hence requiring 11 times as many cases for major depression 
compared to SCZ per genome-wide significant locus. However, the relationship between 
sample size and variant discovery is not linear (Wray et al., 2018) and so observing the 
sample size ratios for discovery will be of interest as sample sizes increase. Very large MDD 
case-control samples will allow novel methods to be applied to assess evidence for genetic 
subsets. Larger data sets are likely to lead to the development of new methods to assess 
genetic heterogeneity (Han et al., 2016). There is a growing interest in machine learning 
methods (Libbrecht & Noble, 2015) as a strategy to identify phenotypically relevant genetic 
subsets, but  cohort heterogeneity must diminish their utility, making large electronic health or 
biobank samples collected and genotyped in a uniform way of most value. 
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Table 1. Description of GWAS data sets for between-sex heterogeneity analyses 
 
Data Set Cases Controls Female 
cases 
Female 
controls 
Male 
cases 
Male 
controls 
Number 
of  
Cohortsa 
PGC29 16,823 25,632 11,438 12,463 5,377 13,022 29b 
GERA 7,162 38,287 5,152 20,650 2,010 17,637 1 
UKB 113,769 208,801 73,292 99,385 40,477 109,426 1 
iPSYCH 18,577 17,637 12,690 8,534 5,887 9,103 1 
Total 156,331 290,357 102,572 141,032 53,751 149,188 32 
 
a: Cohort is defined as the cases and controls with genome-wide genotypes imputed from 
the same set of SNPs that have passed through a common quality control pipeline. Mostly, 
cohort reflects a case-control sample collected by a PGC principal investigator. b: cohorts 
ranged in size from 246 to 3760 cases plus controls. 
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Table 2 Estimates of 𝒉𝑺𝑵𝑷
2 from LDSC applied to sex-specific GWAS summary statistics 
 
 Female (se) Males v1 (se) Males v2 (se) 
P-value 
v1 
P-value 
v2 
K 0.2  0.1  0.2    
u 0  0  0.1    
PGC29 0.20 (0.03) 0.07 (0.04) 0.09 (0.05) 0.61 0.68 
GERA 0.15 (0.04) -0.02 (0.05) -0.03 (0.07) 0.55 0.57 
UKB 0.10 (0.01) 0.07 (0.01) 0.10 (0.01) 0.77 0.94 
iPSYCH 0.23 (0.03) 0.15 (0.04) 0.20 (0.05) 0.77 0.91 
Meta-4 0.11 (0.005) 0.07 (0.006) 0.10 (0.007) 1.6x10-6 0.10 
Meta-6 0.10 (0.005) 0.07 (0.006) 0.10 (0.008) 1.2x10-3 0.60 
Meta-10 0.11 (0.004) 0.07 (0.004) 0.10 (0.005) 1.1x10-8 0.12 
GWAS-Meta 0.08 (0.004) 0.06 (0.005) 0.08 (0.006) 6.6x10-4 0.64 
 
 
ℎ𝑆𝑁𝑃
2  estimates are presented on the liability scale achieved through transformation of the 
LDSC ℎ𝑆𝑁𝑃−𝑐𝑐
2  estimate accounting for the case prevalence in the sample (P), the lifetime risk 
(K) of the disorder, and the proportion of cases in the control sample (u), equation [12]. 
Meta-4: meta-analysis of the ℎ𝑆𝑁𝑃
2  estimates for the 4 data sets (PGC29,GERA,UKB, iPSYCH). 
Meta-6: meta-analysis of the 6 ℎ𝑆𝑁𝑃
2  estimates derived from the genetic covariance estimates 
from bivariate LDSC between the 6 possible same-sex data-set pairwise combinations. Meta-
10: meta-analysis based on all ℎ𝑆𝑁𝑃
2  estimates contributing to Meta-4 and Meta-6. GWAS-
Meta: ℎ𝑆𝑁𝑃
2  estimated from the GWAS summary statistics of the 4 data sets. Versions v1 and v2 
differ by K and u values; v2 hypothesis is that the lifetime risk of MDD is the same in men and 
women but that more cases go unreported in men, and hence cases could be included in a 
screened control set. 
 
 17 
Figure 1. Cohort deviation estimates from the linear regression of 𝒉𝑺𝑵𝑷
2  estimates (from each 
of the 500 samplings of cohorts) on cohort indicator variables set at 1 if the cohort was 
included in the sampling that generated the 𝒉𝑺𝑵𝑷
2  and 0 otherwise.  
In each sampling, cohorts were selected at random until the total case/control sample size 
exceeded 5000. Cohort GWAS results were meta-analysed and these results passed into 
LDscore. ℎ𝑆𝑁𝑃
2  was estimated using the equation 1 transformation (K =0.15) which assumes 
controls are screened. ℎ𝑆𝑁𝑃
2  estimates of samplings were highest, on average, when cohort 
nes1 was included and lowest, on average, when cohort gep3 was included. Wave 1 cohorts 
have an asterisk by their name and cohorts that have unscreened controls are marked by a 
tilde. Continuous lines around data-points are 95% confidence Intervals. For explanation of 
cohort names see Supplementary Table 1.  
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Figure 2.  Impact of choice of lifetime risk on estimate of 𝒉𝑺𝑵𝑷
2 . The graphs shows ℎ𝑆𝑁𝑃
2  on the 
liability scale from equation [2], u (proportion of controls that are unrecognised cases). The 
blue/red dashed lines are positioned at the lifetime risk for males/females. The flat ended 
bars show the 95% confidence intervals of the ℎ𝑆𝑁𝑃
2  estimates   at the chosen lifetime risk. 
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Supplementary Table 2. Bivariate LDSC results of UK Biobank, iPsych, GERA and PGC29 against all other cohorts. The results are presented on the 
observed and liability scale. 
 
a) UK Biobank 
 
 
 
b) iPsych 
 
 
 
 
c) GERA 
 
 
 
 
d) PGC29 
 
T1 T2 SX1 SX2 Nsnp h2_1 se_1 lambda_1 chisq_1 intercept_1 se_int1 ratio_1 h2_2 se_2 lambda_2 chisq_2 intercept_2 se_int2 ratio_2 gencov se_gcov mean_z1z2 cov_interceptse_covint gencor se_gcor gencor_z gencor_p P1 P2 K1 K2 h2l_1 h2l_2 sel_1 sel_2
UKB2 UKB2 F F 1168042 0.0779 0.004 1.2201 1.2623 1.0003 0.0077 0.0013 0.0779 0.004 1.2201 1.2623 1.0003 0.0077 0.0013 0.0779 0.004 1.2623 1.0003 0.0077 1 3.76E-07 2.66E+06 0 0.42444564 0.42444564 0.2 0.2 0.10415283 0.10415283 0.00534803 0.00534803
UKB2 UKB2 F M 1167855 0.0778 0.004 1.2201 1.2623 1.0005 0.0077 0.0018 0.0553 0.0044 1.1459 1.1691 1.0074 0.0072 0.0438 0.057 0.0033 0.183 0.0053 0.0055 0.8693 0.0422 20.5916 3.27E-94 0.42444564 0.27002128 0.2 0.1 0.10401913 0.07378294 0.00534803 0.00587061
UKB2 iPSYCH F F 985138 0.0787 0.0046 1.2431 1.2916 0.9994 0.0098 0 0.1636 0.025 1.0741 1.0709 0.9953 0.0086 0 0.0801 0.0088 0.0992 -0.0032 0.0079 0.7053 0.0912 7.7332 1.05E-14 0.42444564 0.59790803 0.2 0.2 0.10522243 0.22226217 0.00615023 0.03396427
UKB2 iPSYCH F M 984589 0.0792 0.0046 1.2431 1.2914 0.9978 0.0097 0 0.1304 0.0336 1.0466 1.0491 1.0067 0.0089 0.1365 0.0768 0.0092 0.0831 -0.0027 0.0065 0.7554 0.12 6.2949 3.08E-10 0.42444564 0.39272849 0.2 0.1 0.10589094 0.14379418 0.00615023 0.03705126
UKB2 GERA F F 1086853 0.0798 0.0042 1.2267 1.2704 0.993 0.0085 0 0.0783 0.0176 1.0315 1.0357 0.9944 0.0062 0 0.054 0.0065 0.0815 0.008 0.0053 0.683 0.1028 6.647 2.99E-11 0.42444564 0.19967444 0.2 0.2 0.10669314 0.16003487 0.00561543 0.03597208
UKB2 GERA F M 1086266 0.0796 0.0042 1.2267 1.2704 0.9937 0.0086 0 -0.0035 0.0204 1.0105 1.0105 1.0119 0.0068 1.1342 0.0288 0.0066 0.0341 -0.0011 0.005 NA NA NA NA 0.42444564 0.1023057 0.2 0.1 0.10642574 -0.0100226 0.00561543 0.05841722
UKB2 PGC29 F F 1096447 0.0787 0.0044 1.2299 1.2741 0.9982 0.0096 0 0.1502 0.021 1.0496 1.0505 0.9738 0.0072 0 0.0809 0.0079 0.108 0.001 0.0062 0.7444 0.0719 10.3493 4.22E-25 0.42444564 0.47855738 0.2 0.2 0.10522243 0.19659453 0.00588283 0.02748659
UKB2 PGC29 F M 1090938 0.0785 0.0042 1.2299 1.2747 0.9981 0.0093 0 0.0595 0.0304 1.0527 1.0463 1.0242 0.0074 0.523 0.0577 0.0081 0.0713 0.0051 0.0062 0.8443 0.2126 3.9719 7.13E-05 0.42444564 0.29224414 0.2 0.1 0.10495503 0.0756531 0.00561543 0.03865301
UKB2 UKB2 M F 1167855 0.0553 0.0044 1.1459 1.1691 1.0074 0.0072 0.0438 0.0778 0.004 1.2201 1.2623 1.0005 0.0077 0.0018 0.057 0.0033 0.183 0.0053 0.0055 0.8693 0.0422 20.5916 3.27E-94 0.27002128 0.42444564 0.1 0.2 0.07378294 0.10401913 0.00587061 0.00534803
UKB2 UKB2 M M 1168019 0.0553 0.0044 1.1459 1.169 1.0074 0.0071 0.0436 0.0553 0.0044 1.1459 1.169 1.0074 0.0071 0.0436 0.0553 0.0044 1.169 1.0074 0.0071 1 2.08E-07 4.82E+06 0 0.27002128 0.27002128 0.1 0.1 0.07378294 0.07378294 0.00587061 0.00587061
UKB2 iPSYCH M F 985112 0.0547 0.0052 1.1587 1.1868 1.0096 0.0102 0.0516 0.1645 0.025 1.0741 1.0709 0.9949 0.0085 0 0.0496 0.0084 0.0651 0.0043 0.0063 0.5227 0.0867 6.0309 1.63E-09 0.27002128 0.59790803 0.1 0.2 0.0729824 0.22348488 0.006938 0.03396427
UKB2 iPSYCH M M 984565 0.0545 0.0051 1.1587 1.1872 1.0105 0.0102 0.0563 0.131 0.0336 1.0466 1.0491 1.0065 0.0089 0.1327 0.0615 0.0105 0.0657 0.0005 0.0063 0.7282 0.1254 5.8089 6.29E-09 0.27002128 0.39272849 0.1 0.1 0.07271556 0.14445581 0.00680458 0.03705126
UKB2 GERA M F 1086831 0.0571 0.0047 1.1491 1.1746 1.0023 0.0082 0.0133 0.0786 0.0175 1.0315 1.0359 0.9944 0.0062 0 0.0423 0.0064 0.0586 0.0059 0.0053 0.6312 0.1095 5.7634 8.24E-09 0.27002128 0.19967444 0.1 0.2 0.07618456 0.16064803 0.00627088 0.03576769
UKB2 GERA M M 1086239 0.0568 0.0048 1.1491 1.1745 1.003 0.0082 0.0175 -0.0038 0.0204 1.0105 1.0105 1.0121 0.0068 1.1473 0.0396 0.0067 0.045 0.0015 0.0052 NA NA NA NA 0.27002128 0.1023057 0.1 0.1 0.07578429 -0.0108816 0.00640431 0.05841722
UKB2 PGC29 M F 1096421 0.0557 0.0048 1.1523 1.1767 1.0067 0.008 0.0381 0.1505 0.021 1.0496 1.0505 0.9737 0.0072 0 0.0562 0.0078 0.0773 0.0062 0.0059 0.6137 0.0828 7.415 1.22E-13 0.27002128 0.47855738 0.1 0.2 0.07431663 0.19698719 0.00640431 0.02748659
UKB2 PGC29 M M 1090920 0.0553 0.0045 1.1523 1.1774 1.0082 0.0077 0.0461 0.0591 0.0303 1.0527 1.0463 1.0244 0.0074 0.5263 0.0727 0.0086 0.0668 -0.01 0.006 1.2719 0.3248 3.9155 9.02E-05 0.27002128 0.29224414 0.1 0.1 0.07378294 0.0751445 0.00600404 0.03852586
T1 T2 SX1 SX2 Nsnp h2_1 se_1 lambda_1 chisq_1 intercept_1 se_int1 ratio_1 h2_2 se_2 lambda_2 chisq_2 intercept_2 se_int2 ratio_2 gencov se_gcov mean_z1z2 cov_interceptse_covint gencor se_gcor gencor_z gencor_p P1 P2 K1 K2 h2l_1 h2l_2 sel_1 sel_2
iPSYCH UKB2 F F 985138 0.1636 0.025 1.0741 1.0709 0.9953 0.0086 0 0.0787 0.0046 1.2431 1.2916 0.9994 0.0098 0 0.0801 0.0088 0.0992 -0.0032 0.0079 0.7053 0.0912 7.7332 1.05E-14 0.59790803 0.42444564 0.2 0.2 0.22226217 0.10522243 0.03396427 0.00615023
iPSYCH UKB2 F M 985112 0.1645 0.025 1.0741 1.0709 0.9949 0.0085 0 0.0547 0.0052 1.1587 1.1868 1.0096 0.0102 0.0516 0.0496 0.0084 0.0651 0.0043 0.0063 0.5227 0.0867 6.0309 1.63E-09 0.59790803 0.27002128 0.2 0.1 0.22348488 0.0729824 0.03396427 0.006938
iPSYCH iPSYCH F F 994169 0.1687 0.0247 1.0741 1.0705 0.9928 0.0086 0 0.1687 0.0247 1.0741 1.0705 0.9928 0.0086 0 0.1687 0.0247 1.0705 0.9928 0.0086 1 2.25E-06 444807.56 0 0.59790803 0.59790803 0.2 0.2 0.22919088 0.22919088 0.0335567 0.0335567
iPSYCH iPSYCH F M 986451 0.1646 0.0251 1.0741 1.0709 0.9948 0.0086 0 0.1325 0.0331 1.0466 1.0484 1.0052 0.0089 0.1085 0.1463 0.0213 0.0625 0.0059 0.0059 0.9909 0.1675 5.9171 3.28E-09 0.59790803 0.39272849 0.2 0.1 0.22362074 0.14610988 0.03410013 0.0364999
iPSYCH GERA F F 992942 0.1695 0.0247 1.0741 1.0704 0.9925 0.0086 0 0.0713 0.019 1.0315 1.0372 0.997 0.0078 0 0.085 0.0154 0.0392 -0.0043 0.0059 0.7734 0.173 4.471 7.79E-06 0.59790803 0.19967444 0.2 0.2 0.23027774 0.1457278 0.0335567 0.03883349
iPSYCH GERA F M 992614 0.1699 0.0249 1.0741 1.0705 0.9923 0.0086 0 -0.0105 0.0213 1.0075 1.0098 1.0143 0.0078 1.4586 0.0284 0.0174 0.0087 -0.0038 0.0053 NA NA NA NA 0.59790803 0.1023057 0.2 0.1 0.23082117 -0.0300677 0.03382841 0.06099445
iPSYCH PGC29 F F 981498 0.1709 0.0263 1.0741 1.0713 0.992 0.009 0 0.1406 0.0241 1.0557 1.0561 0.9792 0.0088 0 0.1103 0.0199 0.0551 -9.00E-04 0.0064 0.7118 0.1449 4.9121 9.01E-07 0.59790803 0.46762061 0.2 0.2 0.23217974 0.18446436 0.03573041 0.03161871
iPSYCH PGC29 F M 979303 0.1693 0.0256 1.0741 1.0715 0.9928 0.0085 0 0.0421 0.0327 1.0557 1.0492 1.0325 0.009 0.661 0.0565 0.0219 0.0224 -0.0018 0.0065 0.6693 0.3191 2.0977 0.0359 0.59790803 0.30140135 0.2 0.1 0.23000602 0.05258334 0.03477941 0.04084264
iPSYCH UKB2 M F 984589 0.1304 0.0336 1.0466 1.0491 1.0067 0.0089 0.1365 0.0792 0.0046 1.2431 1.2914 0.9978 0.0097 0 0.0768 0.0092 0.0831 -0.0027 0.0065 0.7554 0.12 6.2949 3.08E-10 0.39272849 0.42444564 0.1 0.2 0.14379418 0.10589094 0.03705126 0.00615023
iPSYCH UKB2 M M 984565 0.131 0.0336 1.0466 1.0491 1.0065 0.0089 0.1327 0.0545 0.0051 1.1587 1.1872 1.0105 0.0102 0.0563 0.0615 0.0105 0.0657 0.0005 0.0063 0.7282 0.1254 5.8089 6.29E-09 0.39272849 0.27002128 0.1 0.1 0.14445581 0.07271556 0.03705126 0.00680458
iPSYCH iPSYCH M F 986451 0.1325 0.0331 1.0466 1.0484 1.0052 0.0089 0.1085 0.1646 0.0251 1.0741 1.0709 0.9948 0.0086 0 0.1463 0.0213 0.0625 0.0059 0.0059 0.9909 0.1675 5.9171 3.28E-09 0.39272849 0.59790803 0.1 0.2 0.14610988 0.22362074 0.0364999 0.03410013
iPSYCH iPSYCH M M 993889 0.1381 0.0326 1.0466 1.0481 1.0033 0.0087 0.0693 0.1381 0.0326 1.0466 1.0481 1.0033 0.0087 0.0693 0.1381 0.0326 1.0481 1.0033 0.0087 1 1.17E-05 85155.5596 0 0.39272849 0.39272849 0.1 0.1 0.15228509 0.15228509 0.03594855 0.03594855
iPSYCH GERA M F 992665 0.1381 0.0325 1.0466 1.048 1.0033 0.0087 0.068 0.0698 0.019 1.0315 1.0375 0.9981 0.0079 0 0.0571 0.0163 0.0287 0.0041 0.0051 0.5816 0.1906 3.0506 0.0023 0.39272849 0.19967444 0.1 0.2 0.15228509 0.14266199 0.03583827 0.03883349
iPSYCH GERA M M 992335 0.138 0.0326 1.0466 1.0481 1.0034 0.0087 0.0711 -0.0112 0.0212 1.0075 1.01 1.0148 0.0078 1.4829 0.0342 0.0209 0.0109 -0.0017 0.0057 NA NA NA NA 0.39272849 0.1023057 0.1 0.1 0.15217482 -0.0320722 0.03594855 0.0607081
iPSYCH PGC29 M F 981127 0.1367 0.0343 1.0466 1.0486 1.0039 0.0091 0.0795 0.1413 0.0243 1.0557 1.0562 0.979 0.0089 0 0.1057 0.0198 0.0445 -6.00E-04 0.0057 0.76 0.1727 4.4013 1.08E-05 0.39272849 0.46762061 0.1 0.2 0.15074129 0.18538275 0.03782316 0.03188111
iPSYCH PGC29 M M 978977 0.1361 0.035 1.0466 1.0486 1.004 0.0091 0.0823 0.0415 0.0326 1.0557 1.0492 1.0328 0.0091 0.6657 0.0049 0.0233 0.0292 0.0271 0.0061 0.0655 0.311 0.2107 0.8331 0.39272849 0.30140135 0.1 0.1 0.15007966 0.05183394 0.03859506 0.04071774
T1 T2 SX1 SX2 Nsnp h2_1 se_1 lambda_1 chisq_1 intercept_1 se_int1 ratio_1 h2_2 se_2 lambda_2 chisq_2 intercept_2 se_int2 ratio_2 gencov se_gcov mean_z1z2 cov_interceptse_covint gencor se_gcor gencor_z gencor_p P1 P2 K1 K2 h2l_1 h2l_2 sel_1 sel_2
GERA UKB2 F F 1086853 0.0783 0.0176 1.0315 1.0357 0.9944 0.0062 0 0.0798 0.0042 1.2267 1.2704 0.993 0.0085 0 0.054 0.0065 0.0815 0.008 0.0053 0.683 0.1028 6.647 2.99E-11 0.19967444 0.42444564 0.2 0.2 0.16003487 0.10669314 0.03597208 0.00561543
GERA UKB2 F M 1086831 0.0786 0.0175 1.0315 1.0359 0.9944 0.0062 0 0.0571 0.0047 1.1491 1.1746 1.0023 0.0082 0.0133 0.0423 0.0064 0.0586 0.0059 0.0053 0.6312 0.1095 5.7634 8.24E-09 0.19967444 0.27002128 0.2 0.1 0.16064803 0.07618456 0.03576769 0.00627088
GERA iPSYCH F F 992942 0.0713 0.019 1.0315 1.0372 0.997 0.0078 0 0.1695 0.0247 1.0741 1.0704 0.9925 0.0086 0 0.085 0.0154 0.0392 -0.0043 0.0059 0.7734 0.173 4.471 7.79E-06 0.19967444 0.59790803 0.2 0.2 0.1457278 0.23027774 0.03883349 0.0335567
GERA iPSYCH F M 992665 0.0698 0.019 1.0315 1.0375 0.9981 0.0079 0 0.1381 0.0325 1.0466 1.048 1.0033 0.0087 0.068 0.0571 0.0163 0.0287 0.0041 0.0051 0.5816 0.1906 3.0506 0.0023 0.19967444 0.39272849 0.2 0.1 0.14266199 0.15228509 0.03883349 0.03583827
GERA GERA F F 1185219 0.075 0.0177 1.0285 1.0328 0.9948 0.006 0 0.075 0.0177 1.0285 1.0328 0.9948 0.006 0 0.075 0.0177 1.0328 0.9948 0.006 1 3.94E-07 2540000 0 0.19967444 0.19967444 0.2 0.2 0.15329011 0.15329011 0.03617647 0.03617647
GERA GERA F M 1183456 0.075 0.0176 1.0285 1.0328 0.9947 0.0059 0 -0.0083 0.0188 1.0105 1.0099 1.0131 0.0057 1.3239 0.0357 0.0139 0.0077 -0.0081 0.0041 NA NA NA NA 0.19967444 0.1023057 0.2 0.1 0.15329011 -0.0237678 0.03597208 0.05383548
GERA PGC29 F F 1107418 0.0751 0.0199 1.0315 1.0354 0.9955 0.0072 0 0.152 0.0213 1.0496 1.05 0.9727 0.0072 0 0.0725 0.014 0.0365 -0.0012 0.0052 0.6785 0.1382 4.9082 9.19E-07 0.19967444 0.46762061 0.2 0.2 0.1534945 0.19942093 0.04067298 0.02794517
GERA PGC29 F M 1101653 0.0771 0.0193 1.0315 1.0354 0.9943 0.0071 0 0.0519 0.0302 1.0557 1.0473 1.0281 0.0074 0.5932 0.0407 0.0167 0.0205 0.0023 0.005 0.6428 0.315 2.0407 0.0413 0.19967444 0.30140135 0.2 0.1 0.15758223 0.06482365 0.03944665 0.03772012
GERA UKB2 M F 1086266 -0.0035 0.0204 1.0105 1.0105 1.0119 0.0068 1.1342 0.0796 0.0042 1.2267 1.2704 0.9937 0.0086 0 0.0288 0.0066 0.0341 -0.0011 0.005 NA NA NA NA 0.1023057 0.42444564 0.1 0.2 -0.0100226 0.10642574 0.05841722 0.00561543
GERA UKB2 M M 1086239 -0.0038 0.0204 1.0105 1.0105 1.0121 0.0068 1.1473 0.0568 0.0048 1.1491 1.1745 1.003 0.0082 0.0175 0.0396 0.0067 0.045 0.0015 0.0052 NA NA NA NA 0.1023057 0.27002128 0.1 0.1 -0.0108816 0.07578429 0.05841722 0.00640431
GERA iPSYCH M F 992614 -0.0105 0.0213 1.0075 1.0098 1.0143 0.0078 1.4586 0.1699 0.0249 1.0741 1.0705 0.9923 0.0086 0 0.0284 0.0174 0.0087 -0.0038 0.0053 NA NA NA NA 0.1023057 0.59790803 0.1 0.2 -0.0300677 0.23082117 0.06099445 0.03382841
GERA iPSYCH M M 992335 -0.0112 0.0212 1.0075 1.01 1.0148 0.0078 1.4829 0.138 0.0326 1.0466 1.0481 1.0034 0.0087 0.0711 0.0342 0.0209 0.0109 -0.0017 0.0057 NA NA NA NA 0.1023057 0.39272849 0.1 0.1 -0.0320722 0.15217482 0.0607081 0.03594855
GERA GERA M F 1183456 -0.0083 0.0188 1.0105 1.0099 1.0131 0.0057 1.3239 0.075 0.0176 1.0285 1.0328 0.9947 0.0059 0 0.0357 0.0139 0.0077 -0.0081 0.0041 NA NA NA NA 0.1023057 0.19967444 0.1 0.2 -0.0237678 0.15329011 0.05383548 0.03597208
GERA GERA M M 1184802 -0.0082 0.0187 1.0105 1.01 1.0131 0.0057 1.3198 -0.0082 0.0187 1.0105 1.01 1.0131 0.0057 1.3198 -0.0083 0.0187 1.01 1.0131 0.0057 NA NA NA NA 0.1023057 0.1023057 0.1 0.1 -0.0234814 -0.0234814 0.05354912 0.05354912
GERA PGC29 M F 1107056 -0.0071 0.0198 1.0105 1.0096 1.0125 0.0067 1.2973 0.1525 0.0213 1.0496 1.0499 0.9723 0.0072 0 0.0306 0.0149 0.0118 -0.0018 0.0049 NA NA NA NA 0.1023057 0.46762061 0.1 0.2 -0.0203315 0.20007692 0.05669907 0.02794517
GERA PGC29 M M 1101303 -0.0077 0.0196 1.0105 1.0098 1.013 0.0067 1.3183 0.0526 0.0303 1.0557 1.0473 1.0278 0.0074 0.5879 0.046 0.0161 0.0182 5.00E-04 0.0045 NA NA NA NA 0.1023057 0.30140135 0.1 0.1 -0.0220496 0.06569795 0.05612635 0.03784502
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* ANNOTATIONS: T1/2 - Trait 1/2; SX1/2 - Sex in trait 1/2; Nsnp - Total number of SNPs;  h2_1/2 - SNP-heritability for trait 1/2; se_1/2 - standard error 
of the SNP-heritability for trait 1/2; lambda_1/2 - lambda GC = [median(chi^2)/0.4549]; chisq_1/2 - regression chi-squared for trait 1/2; 
intercept_1/2 - regression intercept for trait 1/2; se_int1/2 - standard error of the intercept for trait 1/2; ratio_1/2 = (intercept-1)/(mean(chi^2)-1); 
gencov - total observed scale genetic covariance; se_gcov - standard error of the genetic covariance; mean_z1z2 - mean product of Z-scores 
(cross-trait chi-square); cov_intercept - cross-trait LD Score regression intercept; se_covint  - standard error of the cross-trait intercept; gencor - 
genetic correlation; se_gcor - standard error of the genetic correlation; gencor_z = gencor/se_gcor; gencor_p - p-value for genetic correlation; 
P1/2 - sample prevalence;  K1/2 - lifetime risk; h2l_1/2 - SNP-heritability on liability scale; se_l1/2 - standard error of the SNP-heritability on liability 
scale                    
                    
                      
T1 T2 SX1 SX2 Nsnp h2_1 se_1 lambda_1 chisq_1 intercept_1 se_int1 ratio_1 h2_2 se_2 lambda_2 chisq_2 intercept_2 se_int2 ratio_2 gencov se_gcov mean_z1z2 cov_interceptse_covint gencor se_gcor gencor_z gencor_p P1 P2 K1 K2 h2l_1 h2l_2 sel_1 sel_2
PGC29 UKB2 F F 1096447 0.1502 0.021 1.0496 1.0505 0.9738 0.0072 0 0.0787 0.0044 1.2299 1.2741 0.9982 0.0096 0 0.0809 0.0079 0.108 0.001 0.0062 0.7444 0.0719 10.3493 4.22E-25 0.46762061 0.42444564 0.2 0.2 0.19705937 0.10522243 0.02755158 0.00588283
PGC29 UKB2 F M 1096421 0.1505 0.021 1.0496 1.0505 0.9737 0.0072 0 0.0557 0.0048 1.1523 1.1767 1.0067 0.008 0.0381 0.0562 0.0078 0.0773 0.0062 0.0059 0.6137 0.0828 7.415 1.22E-13 0.46762061 0.27002128 0.2 0.1 0.19745297 0.07431663 0.02755158 0.00640431
PGC29 iPSYCH F F 981498 0.1406 0.0241 1.0557 1.0561 0.9792 0.0088 0 0.1709 0.0263 1.0741 1.0713 0.992 0.009 0 0.1103 0.0199 0.0551 -9.00E-04 0.0064 0.7118 0.1449 4.9121 9.01E-07 0.46762061 0.59790803 0.2 0.2 0.18446436 0.23217974 0.03161871 0.03573041
PGC29 iPSYCH F M 981127 0.1413 0.0243 1.0557 1.0562 0.979 0.0089 0 0.1367 0.0343 1.0466 1.0486 1.0039 0.0091 0.0795 0.1057 0.0198 0.0445 -6.00E-04 0.0057 0.76 0.1727 4.4013 1.08E-05 0.46762061 0.39272849 0.2 0.1 0.18538275 0.15074129 0.03188111 0.03782316
PGC29 GERA F F 1107418 0.152 0.0213 1.0496 1.05 0.9727 0.0072 0 0.0751 0.0199 1.0315 1.0354 0.9955 0.0072 0 0.0725 0.014 0.0365 -0.0012 0.0052 0.6785 0.1382 4.9082 9.19E-07 0.46762061 0.19967444 0.2 0.2 0.19942093 0.1534945 0.02794517 0.04067298
PGC29 GERA F M 1107056 0.1525 0.0213 1.0496 1.0499 0.9723 0.0072 0 -0.0071 0.0198 1.0105 1.0096 1.0125 0.0067 1.2973 0.0306 0.0149 0.0118 -0.0018 0.0049 NA NA NA NA 0.46762061 0.1023057 0.2 0.1 0.20007692 -0.0203315 0.02794517 0.05669907
PGC29 PGC29 F F 1108969 0.1529 0.0213 1.0496 1.05 0.9722 0.0072 0 0.1529 0.0213 1.0496 1.05 0.9722 0.0072 0 0.1529 0.0213 1.05 0.9722 0.0072 1 2.36E-07 4230000 0 0.46762061 0.46762061 0.2 0.2 0.20060172 0.20060172 0.02794517 0.02794517
PGC29 PGC29 F M 1100025 0.1518 0.0227 1.0496 1.0505 0.9729 0.0073 0 0.0529 0.0304 1.0557 1.0473 1.0277 0.0075 0.5852 0.0834 0.0187 0.0426 0.0057 0.0054 0.9315 0.322 2.8932 0.0038 0.46762061 0.30140135 0.2 0.1 0.19915854 0.06607266 0.02978194 0.03796992
PGC29 UKB2 M F 1090938 0.0595 0.0304 1.0527 1.0463 1.0242 0.0074 0.523 0.0785 0.0042 1.2299 1.2747 0.9981 0.0093 0 0.0577 0.0081 0.0713 0.0051 0.0062 0.8443 0.2126 3.9719 7.13E-05 0.30140135 0.42444564 0.1 0.2 0.07431613 0.10495503 0.03796992 0.00561543
PGC29 UKB2 M M 1090920 0.0591 0.0303 1.0527 1.0463 1.0244 0.0074 0.5263 0.0553 0.0045 1.1523 1.1774 1.0082 0.0077 0.0461 0.0727 0.0086 0.0668 -0.01 0.006 1.2719 0.3248 3.9155 9.02E-05 0.30140135 0.27002128 0.1 0.1 0.07381652 0.07378294 0.03784502 0.00600404
PGC29 iPSYCH M F 979303 0.0421 0.0327 1.0557 1.0492 1.0325 0.009 0.661 0.1693 0.0256 1.0741 1.0715 0.9928 0.0085 0 0.0565 0.0219 0.0224 -0.0018 0.0065 0.6693 0.3191 2.0977 0.0359 0.30140135 0.59790803 0.1 0.2 0.05258334 0.23000602 0.04084264 0.03477941
PGC29 iPSYCH M M 978977 0.0415 0.0326 1.0557 1.0492 1.0328 0.0091 0.6657 0.1361 0.035 1.0466 1.0486 1.004 0.0091 0.0823 0.0049 0.0233 0.0292 0.0271 0.0061 0.0655 0.311 0.2107 0.8331 0.30140135 0.39272849 0.1 0.1 0.05183394 0.15007966 0.04071774 0.03859506
PGC29 GERA M F 1101653 0.0519 0.0302 1.0557 1.0473 1.0281 0.0074 0.5932 0.0771 0.0193 1.0315 1.0354 0.9943 0.0071 0 0.0407 0.0167 0.0205 0.0023 0.005 0.6428 0.315 2.0407 0.0413 0.30140135 0.19967444 0.1 0.2 0.06482365 0.15758223 0.03772012 0.03944665
PGC29 GERA M M 1101303 0.0526 0.0303 1.0557 1.0473 1.0278 0.0074 0.5879 -0.0077 0.0196 1.0105 1.0098 1.013 0.0067 1.3183 0.046 0.0161 0.0182 5.00E-04 0.0045 NA NA NA NA 0.30140135 0.1023057 0.1 0.1 0.06569795 -0.0220496 0.03784502 0.05612635
PGC29 PGC29 M F 1100025 0.0529 0.0304 1.0557 1.0473 1.0277 0.0075 0.5852 0.1518 0.0227 1.0496 1.0505 0.9729 0.0073 0 0.0834 0.0187 0.0426 0.0057 0.0054 0.9315 0.322 2.8932 0.0038 0.30140135 0.46762061 0.1 0.2 0.06607266 0.19915854 0.03796992 0.02978194
PGC29 PGC29 M M 1103168 0.0527 0.0303 1.0557 1.0473 1.0278 0.0074 0.5869 0.0527 0.0303 1.0557 1.0473 1.0278 0.0074 0.5869 0.0527 0.0303 1.0473 1.0278 0.0074 1 3.15E-06 317182.424 0 0.30140135 0.30140135 0.1 0.1 0.06582286 0.06582286 0.03784502 0.03784502
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Supplementary Table 3: Sex-specific SNP-heritabilities and rg
PGC2_M PGC2_F GERA_M GERA_F UKB_M UKB_F iPSYCH_M iPSYCH_F
PGC2_M 0.07 (0.04) 0.93 (0.32) _ 0.64 (0.32) 1.27 (0.32) 0.84 (0.21) 0.07 (0.31)
 * 0.67 (0.32)
PGC2_F 0.20 (0.03) _ 0.68 (0.14)
*
0.61 (0.08)
 *
0.74 (0.07)
 * 0.76 (0.17) 0.72 (0.14)
 *
GERA_M -0.02 (0.05) _ _ _ _ _
GERA_F 0.15 (0.04) 0.63 (0.11)
 *
0.68 (0.10)
*
0.58 (0.19)
* 0.77 (0.17)
UKB_M  0.07 (0.01) 0.87 (0.04) 0.82 (0.15) 0.57 (0.11)
*
UKB_F 0.10 (0.01) 0.83 (0.15) 0.63 (0.11)
*
iPSYCH_M 0.15 (0.04) 0.99 (0.17)
iPSYCH_F 0.23 (0.03)
h2-SNP estimates (diagonals in bold) assume lifetime risks of K  = 0.10 for males and K = 0.20 for females. 
Standard error s of estimates are in brackets.
* genetic correlation significantly lower than 1. 
Given the negative  h2-SNP for GERA_M, the genetic correlations for this data set are non-estimable,
despite non-zero genetic covariances between GERA_M with other data sets.
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Supplementary Table 4: Beta coefficients from 500 sampling analyses used in plotting Figure 1 
 
 
 
Beta coefficients from multiple regression of 500 sampling iterations where each cohort 
indicator was set up as described in Figure 1. Regression intercept was 0.235306. Description 
of cohort names can be found in Supplementary Table 1. Com_clin variable coded as 
follows: Community = 0, Outpatients = 1, In/Out = 2, and Inpatients = 3. 
 
cohort est se wave unscreened Com_clin
cof3 -0.0013 0.006 2 0 2
col3 -0.0502 0.007 2 0 0
edi2 0.0045 0.006 2 0 2
gens 0.0221 0.008 1 0 2
grdg -0.0022 0.006 2 0 1
grnd -0.0061 0.007 2 0 2
gsk2 -0.0237 0.007 1 0 2
i2b3 -0.0244 0.007 2 0 1
mmi2 0.0060 0.007 1 0 3
mmo4 0.0157 0.006 2 0 3
nes1 0.0552 0.009 1 0 1
qi3c -0.0417 0.007 1 0 0
qi6c -0.0305 0.007 1 0 0
qio2 -0.0149 0.007 2 0 0
rad3 0.0301 0.010 1 0 1
rau2 -0.0038 0.007 2 0 1
rde4 -0.0105 0.006 2 0 1
roc3 -0.0138 0.006 2 0 1
rot4 -0.0424 0.007 2 0 0
shp0 -0.0029 0.006 2 0 0
shpt 0.0013 0.006 2 0 0
twg2 -0.0347 0.008 2 0 0
boma -0.0228 0.007 1 1 3
gep3 -0.0861 0.006 2 1 1
jjp2 -0.0145 0.007 2 1 2
pfm2 -0.0353 0.006 2 1 1
rage -0.0071 0.006 1 1 1
rai2 0.0052 0.006 2 1 1
stm2 -0.0547 0.008 1 1 1
